Physician profile
Eric J Farinas
NPI 1841277613
$11,874.76
in general payments reported to CMS, 2019-2025
50 companies · $2,141 in 2025
The $2,141 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $1,117 · 2021: $1,564 · 2022: $1,301 · 2023: $2,098 · 2024: $2,263 · 2025: $2,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,501.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,329.75 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,091.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,007.81 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $908.71 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $841.60 | 2019-2025 | |
| Pfizer INC. | $783.55 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $765.99 | 2019-2022 | |
| Lilly USA, LLC | $706.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $585.47 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $457.85 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.26 | 2019-2025 | Jardiance |
| Amgen INC. | $313.43 | 2019-2025 | Evenity, Prolia, Repatha |
| Inspire Medical Systems, INC. | $255.58 | 2023-2025 | Inspire |
| Dexcom, INC. | $253.57 | 2023-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $244.14 | 2019-2023 | Ajovy |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Farinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.